Follow
Johann de Bono
Johann de Bono
Verified email at icr.ac.uk - Homepage
Title
Cited by
Cited by
Year
Increased survival with enzalutamide in prostate cancer after chemotherapy
HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R De Wit, ...
New England Journal of Medicine 367 (13), 1187-1197, 2012
50882012
Abiraterone and increased survival in metastatic prostate cancer
JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ...
New England Journal of Medicine 364 (21), 1995-2005, 2011
49672011
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
PC Fong, DS Boss, TA Yap, A Tutt, P Wu, M Mergui-Roelvink, P Mortimer, ...
New England Journal of Medicine 361 (2), 123-134, 2009
42702009
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
JS De Bono, S Oudard, M Ozguroglu, S Hansen, JP Machiels, I Kocak, ...
The Lancet 376 (9747), 1147-1154, 2010
39132010
Integrative clinical genomics of advanced prostate cancer
D Robinson, EM Van Allen, YM Wu, N Schultz, RJ Lonigro, JM Mosquera, ...
Cell 161 (5), 1215-1228, 2015
35182015
Enzalutamide in metastatic prostate cancer before chemotherapy
TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
New England Journal of Medicine 371 (5), 424-433, 2014
32622014
Abiraterone in metastatic prostate cancer without previous chemotherapy
CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ...
New England Journal of Medicine 368 (2), 138-148, 2013
31502013
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer
JS De Bono, HI Scher, RB Montgomery, C Parker, MC Miller, H Tissing, ...
Clinical cancer research 14 (19), 6302-6309, 2008
24512008
DNA-repair defects and olaparib in metastatic prostate cancer
J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ...
New England Journal of Medicine 373 (18), 1697-1708, 2015
22262015
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage …
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
The Lancet 387 (10024), 1163-1177, 2016
20262016
Abiraterone for prostate cancer not previously treated with hormone therapy
ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ...
New England Journal of Medicine 377 (4), 338-351, 2017
16942017
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo …
K Fizazi, HI Scher, A Molina, CJ Logothetis, KN Chi, RJ Jones, ...
The lancet oncology 13 (10), 983-992, 2012
16442012
Olaparib for metastatic castration-resistant prostate cancer
J de Bono, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ...
New England Journal of Medicine 382 (22), 2091-2102, 2020
15662020
Inherited DNA-repair gene mutations in men with metastatic prostate cancer
CC Pritchard, J Mateo, MF Walsh, N De Sarkar, W Abida, H Beltran, ...
New England Journal of Medicine 375 (5), 443-453, 2016
15212016
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall …
CJ Ryan, MR Smith, K Fizazi, F Saad, PFA Mulders, CN Sternberg, ...
The Lancet Oncology 16 (2), 152-160, 2015
15042015
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
G Vlachogiannis, S Hedayat, A Vatsiou, Y Jamin, J Fernández-Mateos, ...
Science 359 (6378), 920-926, 2018
14332018
Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3
HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ...
Journal of Clinical Oncology 34 (12), 1402, 2016
12432016
Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer
O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ST Tagawa, ...
New England Journal of Medicine 385 (12), 1091-1103, 2021
11992021
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
PC Fong, TA Yap, DS Boss, CP Carden, M Mergui-Roelvink, C Gourley, ...
Journal of clinical oncology 28 (15), 2512-2519, 2010
11052010
Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostrate cancer commonly remains hormone driven
G Attard, AH Reid, TA Yap, F Raynaud, M Dowsett
Journal of clinical oncology 26 (28), 4563-4571, 2008
10692008
The system can't perform the operation now. Try again later.
Articles 1–20